09.12.2020 | Correction
Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab
Erschienen in: Pediatric Nephrology | Ausgabe 4/2021
Einloggen, um Zugang zu erhalten